Centene & HMHB Hawaii Expand Partnership for Maternal Care

28.03.25 16:06 Uhr

Werte in diesem Artikel
Aktien

55,91 EUR 0,18 EUR 0,32%

Indizes

5.396,5 PKT -274,5 PKT -4,84%

935,5 PKT -8,9 PKT -0,94%

Centene Corporation CNC recently announced that its subsidiary, 'Ohana Health Plan, is strengthening its commitment to maternal and child health by expanding its partnership with Healthy Mothers Healthy Babies Coalition of Hawaii (HMHB Hawaii). The company has announced an additional $300,000 investment in the Mana 'Ohana program, bringing its total contribution to $500,000.This collaboration would enhance access to a program developed to support women and their newborn children in the perinatal period. This move bodes well for CNC as by enhancing prenatal and postpartum care services, 'Ohana Health Plan is helping to reduce healthcare costs, particularly by lowering the need for neonatal intensive care unit costs. Improved maternal and infant health outcomes lead to financial efficiencies, benefiting both patients and the healthcare system.This partnership with HMHB Hawaii reinforces the company’s commitment to culturally responsive and accessible care. This not only strengthens brand trust but also helps expand CNC’s market share in Hawaii’s managed care sector. As a result of the latest move, 'Ohana Health Plan is likely to attract new members as well as retain existing ones within its plans. A growing customer base brings higher premiums, which usually account for a major chunk of a health insurer’s top line.Centene’s total membership was 28.6 million as of Dec. 31, 2024, which grew 4.1% year over year. Meanwhile, premiums rose 5% year over year in 2024. In March 2025, CNC’s Illinois subsidiary, Meridian Health Plan of Illinois, was chosen by the Illinois Department of Health and Family Services to continue providing enhanced managed care services to 77,000 dually eligible residents via a Fully Integrated Dual Eligible Special Needs Plan. CNC’s Share Price Performance & Zacks RankShares of Centene have risen 2.8% in the past month compared with the industry’s 8.9% growth. CNC currently carries a Zacks Rank #3 (Hold).Image Source: Zacks Investment ResearchStocks to ConsiderSome better-ranked stocks from the Medical space are Option Care Health, Inc. OPCH, ADMA Biologics, Inc. ADMA and Bioventus Inc. BVS. While Option Care sports a Zacks Rank #1 (Strong Buy) at present, ADMA Biologics and Bioventus carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Option Care’s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 15.91%. The consensus estimate for OPCH’s 2025 earnings and revenues indicates an improvement of 37.4% and 8.9%, respectively, from the 2024 figures.  The consensus estimate for Option Care’s earnings has moved 34.1% north in the past 30 days.ADMA Biologics’ earnings outpaced the Zacks Consensus Estimate in three of the trailing four quarters and missed the mark once, the average surprise being 32.80%. The consensus estimate for ADMA’s 2025 earnings and revenues implies an improvement of 44.9% and 16.3% from the respective 2024 figures. The consensus estimate for ADMA Biologics’ 2025 earnings has moved 1.4% north in the past seven days.Bioventus’ earnings outpaced the Zacks Consensus Estimate in three of the trailing four quarters and matched the mark once, the average surprise being 119.53%. The consensus estimate for BVS’ 2025 earnings indicates an improvement of 34.7% from the 2024 figure.   The consensus estimate for Bioventus’ 2025 earnings has moved 43.5% north in the past seven days.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Centene Corporation (CNC): Free Stock Analysis Report ADMA Biologics Inc (ADMA): Free Stock Analysis Report Option Care Health, Inc. (OPCH): Free Stock Analysis Report Bioventus Inc. (BVS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Centene und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Centene

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Centene

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Centene Corp.

Wer­bung

Analysen zu Centene Corp.

DatumRatingAnalyst
20.10.2017Centene OutperformBMO Capital Markets
05.04.2017Centene BuyDeutsche Bank AG
08.02.2017Centene OverweightBarclays Capital
07.02.2017Centene OverweightCantor Fitzgerald
20.06.2016Centene OverweightBarclays Capital
DatumRatingAnalyst
20.10.2017Centene OutperformBMO Capital Markets
05.04.2017Centene BuyDeutsche Bank AG
08.02.2017Centene OverweightBarclays Capital
07.02.2017Centene OverweightCantor Fitzgerald
20.06.2016Centene OverweightBarclays Capital
DatumRatingAnalyst
15.06.2015Centene HoldDeutsche Bank AG
15.06.2015Centene Mkt PerformFBR Capital
28.04.2015Centene Mkt PerformFBR Capital
11.02.2015Centene NeutralUBS AG
15.12.2014Centene HoldDeutsche Bank AG
DatumRatingAnalyst
05.12.2006Update Centene Corp.: SellGoldman Sachs
12.06.2006Update Centene Corp.: SellMatrix Research

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Centene Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen